

Note: This document has been translated from the Japanese original for reference purpose only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



August 3, 2026

Noevir Holdings Announces Consolidated Results for the First Nine Months of the Fiscal Year Ending September 30, 2026 (based on Japan GAAP)

Trade name: Noevir Holdings Co., Ltd.
 Listing: Tokyo Stock Exchange, Prime Market (Securities Code: 4928)
 URL: <https://www.noevirholdings.co.jp/>
 Representative: Takashi Okura, President and CEO
 Contact: Junya Baba, General Manager, Accounting
 Tel. +81-78-303-5121

Date of commencement of dividend payments: –
 Supplemental materials for the financial results prepared: None
 Results briefing for the reporting period held: None

(Amounts under one million yen have been rounded down)

1. Operating results for the first nine months of the fiscal year ending September 30, 2026 (October 1, 2025 to June 30, 2026)

(1) Consolidated operating results

(Millions of yen; percentage figures denote year-on-year change)

	Net sales		Operating income		Ordinary income		Net income attributable to owners of the parent
Nine months ended June 30, 2026	46,075	(2.6)%	6,895	(13.9)%	7,290	(13.4)%	4,089 (0.8)%
Nine months ended June 30, 2025	47,283	(2.0)%	8,008	(11.2)%	8,422	(8.1)%	4,123 (8.2)%

Note: Comprehensive income:
 Nine months ended June 30, 2026: 5,394 million yen [29.4%]
 Nine months ended June 30, 2025: 4,168 million yen [(21.5)%]

	EPS (Yen)	Diluted EPS (Yen)
Nine months ended June 30, 2026	119.72	—
Nine months ended June 30, 2025	120.73	—

(2) Consolidated financial position

(Millions of yen)

	Total assets	Net assets	Equity ratio (%)
As of June 30, 2026	73,500	51,510	69.4
As of September 30, 2025	76,492	54,209	70.3

[Reference] Equity:
 As of June 30, 2026: 51,017 million yen
 As of September 30, 2025: 53,767 million yen

2. Cash dividends

(Yen)

	Annual dividends				
	1st quarter	2nd quarter	3rd quarter	Year-end	Total
Fiscal year ended September 30, 2025	—	0.00	—	230.00	230.00
Fiscal year ended September 30, 2026	—	0.00	—		
Fiscal year ending September 30, 2026 (forecast)				230.00	230.00

Note: Revisions from the most recently announced dividend forecast: None

3. Consolidated earnings forecasts for the fiscal year ending September 30, 2026 (October 1, 2025 to September 30, 2026)

(Millions of yen; percentage figures denote year-on-year change)

	Net sales		Operating income		Ordinary income		Net income attributable to owners of the parent		EPS (Yen)
Full year	65,000	0.4%	11,400	2.9%	11,800	0.2%	8,200	2.1%	240.07

Note: Revisions from the most recently announced consolidated earnings forecast: None

* Notes

(1) Significant changes in the scope of consolidation during the period: None

(2) Special accounting treatment for preparation of quarterly consolidated financial statements: None

(3) Changes in accounting policies, changes in accounting estimates, and restatement

1) Changes associated with revision in accounting standards: None

2) Other changes: None

3) Changes in accounting estimates: None

4) Restatement: None

(4) Shares outstanding (common stock)

1) Shares outstanding (including treasury stock)

As of June 30, 2026: 34,156,623

As of September 30, 2025: 34,156,623

2) Treasury shares outstanding

As of June 30, 2026: 417

As of September 30, 2025: 416

3) Average shares outstanding over quarter

Nine months ended June 30, 2026: 34,156,207

Nine months ended June 30, 2025: 34,156,207

* Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: None

* Explanation regarding the appropriate use of business performance forecasts

Forward-looking statements included in these materials, such as forecasts of business performance, are based on information known to the Company's management as of the time of writing, and reflect judgments believed to be reasonable on the basis of that information. There is, therefore, a possibility that actual business performance figures will differ substantially from our forecasts as a result of changes in the economic situation and other unforeseeable factors. Please refer to "(3) Estimates and forecasts pertaining to future plans and business results" under "1. Operating results and financial information" on page 5 of the Attached Material.

Contents of the Attached Material

1. Operating results and financial information	4
(1) Operating results for the first nine months of the fiscal year ending September 30, 2026	4
(2) Financial position as of June 30, 2026	5
(3) Estimates and forecasts pertaining to future plans and business results	5
2. Quarterly consolidated financial statements and notes.....	6
(1) Quarterly consolidated balance sheets	6
(2) Quarterly consolidated statements of income and comprehensive income.....	8
(3) Notes to quarterly consolidated financial statements	10
(Note on assumptions for going concern).....	10
(Note on significant changes in the amount of shareholders' equity)	10
(Note on statement of cash flows)	10
(Note on segment information)	10

1. Operating results and financial information

(1) Operating results for the first nine months of the fiscal year ending September 30, 2026

Consolidated operating results for the first nine months of the fiscal year ending September 30, 2026
(October 1, 2025 to June 30, 2026)

	Nine months ended June 30, 2025		Nine months ended June 30, 2026		Change (Millions of yen)	Change (%)
	Net sales (Millions of yen)	% of Total	Net sales (Millions of yen)	% of Total		
Net sales	47,283	100.0	46,075	100.0	(1,207)	(2.6)
Cosmetics	37,412	79.1	36,422	79.0	(990)	(2.6)
Pharmaceuticals & Health Food	8,374	17.7	8,002	17.4	(372)	(4.4)
Other	1,495	3.2	1,650	3.6	154	10.4

	Nine months ended June 30, 2025		Nine months ended June 30, 2026		Change (Millions of yen)	Change (%)
	Amount (Millions of yen)	% of Net sales	Amount (Millions of yen)	% of Net sales		
Operating income	8,008	16.9	6,895	15.0	(1,112)	(13.9)
Ordinary income	8,422	17.8	7,290	15.8	(1,132)	(13.4)
Net income attributable to owners of the parent	4,123	8.7	4,089	8.9	(34)	(0.8)

During the first nine months of fiscal 2026 (October 1, 2025 to June 30, 2026), economic trends remained uncertain due to factors such as the impact of conditions in the Middle East, although some signs of a moderate recovery were observed.

In this environment, the Company is working to realize the concept of its medium- to long-term strategy: “Realizing steady corporate growth by securing sustainability in every Group business segment.”

As a result, net sales for the first nine months of fiscal 2026 came to 46,075 million yen (down 2.6% year on year), operating income was 6,895 million yen (down 13.9%), ordinary income was 7,290 million yen (down 13.4%), and net income attributable to owners of the parent came to 4,089 million yen (down 0.8%).

In the Cosmetics segment, net sales totaled 36,422 million yen (down 2.6% year on year), and segment income came to 8,084 million yen (down 9.9%).

In the Pharmaceuticals & Health Food segment, net sales totaled 8,002 million yen (down 4.4% year on year), and segment income came to 562 million yen (down 24.6%).

In the Other segment, net sales totaled 1,650 million yen (up 10.4% year on year), and segment income came to 155 million yen (up 13.5%).

(2) Financial position as of June 30, 2026

Total assets as of June 30, 2026 stood at 73,500 million yen, a decrease of 2,991 million yen from the previous fiscal year-end. This was mainly due to a decrease in cash and deposits of 12,701 million yen, while there was an increase in securities of 9,946 million yen.

Total liabilities came to 21,990 million yen, a decrease of 293 million yen from the previous fiscal year-end. This mainly reflected decreases in income tax payable of 511 million yen and guarantee deposits received of 313 million yen, while there was an increase in deferred tax liabilities of 401 million yen.

Net assets came to 51,510 million yen, a decrease of 2,698 million yen from the previous fiscal year-end.

This was primarily attributable to a decrease in retained earnings of 3,766 million yen, due to the payment of 7,855 million yen in dividends at the previous fiscal year-end, which was partly offset by net income attributable to owners of the parent of 4,089 million yen, while there was an increase in net unrealized gain on other securities of 753 million yen.

As a result, the equity ratio stood at 69.4%.

(3) Estimates and forecasts pertaining to future plans and business results

The consolidated business performance forecasts for the full year ending September 30, 2026, announced on November 7, 2025, remain unchanged.

2. Quarterly consolidated financial statements and notes

(1) Quarterly consolidated balance sheets

(Millions of yen)

	Previous fiscal year (As of September 30, 2025)	As of June 30, 2026
ASSETS		
Current assets		
Cash and deposits	26,930	14,229
Notes and accounts receivable	12,110	9,476
Securities	—	9,946
Merchandise and finished goods	5,974	8,065
Work in progress	183	181
Raw materials and purchased supplies	1,525	1,742
Other	2,166	2,572
Allowance for doubtful accounts	(7)	(7)
Total current assets	48,884	46,205
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	4,419	4,100
Equipment and vehicles, net	547	437
Land	14,976	14,488
Lease assets, net	686	632
Construction in progress	545	630
Other, net	221	309
Total property, plant and equipment	21,397	20,599
Intangible assets		
Goodwill	125	100
Software	89	845
Other	969	110
Total intangible assets	1,184	1,056
Investments and other assets		
Investment securities	2,866	3,969
Deferred tax assets	1,070	943
Other	1,106	741
Allowance for doubtful accounts	(17)	(15)
Total investments and other assets	5,026	5,639
Total non-current assets	27,608	27,295
Total assets	76,492	73,500

(Millions of yen)

	Previous fiscal year (As of September 30, 2025)	As of June 30, 2026
LIABILITIES		
Current liabilities		
Notes and accounts payable	3,240	3,481
Lease obligations	85	84
Other accounts payable	2,160	2,362
Income tax payable	2,043	1,532
Provision for bonuses	25	9
Other	2,290	2,155
Total current liabilities	9,847	9,625
Long-term liabilities		
Lease obligations	657	600
Guarantee deposits received	10,751	10,438
Deferred tax liabilities	690	1,092
Net defined benefit liability	9	11
Other	326	220
Total long-term liabilities	12,436	12,364
Total liabilities	22,283	21,990
NET ASSETS		
Shareholders' equity		
Common stock	7,319	7,319
Retained earnings	44,113	40,346
Treasury stock	(2)	(2)
Total shareholders' equity	51,429	47,663
Accumulated other comprehensive income		
Net unrealized gain on other securities	1,751	2,505
Foreign currency translation adjustments	585	848
Total accumulated other comprehensive income	2,337	3,354
Non-controlling interests	441	493
Total net assets	54,209	51,510
Total liabilities and net assets	76,492	73,500

(2) Quarterly consolidated statements of income and comprehensive income
Quarterly consolidated statements of income
First nine months of the fiscal year ending September 30, 2026

(Millions of yen)

	Nine months ended June 30, 2025	Nine months ended June 30, 2026
Net sales	47,283	46,075
Cost of sales	15,213	14,690
Gross profit	32,069	31,384
Selling, general and administrative expenses	24,060	24,488
Operating income	8,008	6,895
Non-operating income		
Interest income	63	105
Dividend income	29	40
Gain on currency translation	25	98
Insurance claim income	193	0
Other	102	148
Total	414	394
Non-operating expenses		
Other	0	0
Total	0	0
Ordinary income	8,422	7,290
Extraordinary income		
Gain on sale of non-current assets	15	924
Gain on revision of retirement benefit plan	85	—
Total	101	924
Extraordinary losses		
Loss on disposal of non-current assets	1	0
Impairment loss	—	120
Loss on cancellation of insurance policies	—	164
Total	1	285
Income before income taxes	8,523	7,929
Income taxes – basic	3,990	3,445
Income taxes – deferred	258	178
Total	4,249	3,623
Net income	4,273	4,305
Net income attributable to non-controlling interests	149	216
Net income attributable to owners of the parent	4,123	4,089

Quarterly consolidated statements of comprehensive income
First nine months of the fiscal year ending September 30, 2026

(Millions of yen)

	Nine months ended June 30, 2025	Nine months ended June 30, 2026
Net income	4,273	4,305
Other comprehensive income		
Net unrealized gain on other securities	(187)	753
Foreign currency translation adjustments	61	335
Remeasurements of defined benefit plans, net of tax	20	—
Total	(105)	1,089
Comprehensive income	4,168	5,394
(Breakdown)		
Comprehensive income attributable to owners of the parent	4,027	5,106
Comprehensive income attributable to non-controlling interests	140	288

(3) Notes to quarterly consolidated financial statements
(Note on assumptions for going concern)

Not applicable

(Note on significant changes in the amount of shareholders' equity)

Not applicable

(Note on statement of cash flows)

The quarterly consolidated statement of cash flows for the third quarter of the current fiscal year has not been prepared. Depreciation (including amortization related to intangible assets other than goodwill), and amortization of goodwill for the nine months ended June 30 are as follows.

	(Millions of yen)	
	Nine months ended June 30, 2025	Nine months ended June 30, 2026
Depreciation	611	746
Amortization of goodwill	25	25

(Note on segment information)

I Consolidated results for the first nine months of the fiscal year ending September 30, 2025
(October 1, 2024 to June 30, 2025)

1. Net sales and income (loss) data, by reportable segment

	(Millions of yen)					
	Cosmetics	Pharmaceuticals & Health Food	Other	Total	Adjustment (Note 1)	Amounts included in quarterly consolidated statements of income (Note 2)
Net sales						
Revenue from contracts with customers	37,412	8,374	1,430	47,217	—	47,217
Other revenue	—	—	65	65	—	65
Sales, external	37,412	8,374	1,495	47,283	—	47,283
Intersegment sales	—	—	197	197	(197)	—
Total	37,412	8,374	1,693	47,481	(197)	47,283
Segment income	8,974	746	137	9,858	(1,850)	8,008

(Note 1) Intersegment eliminations totaling 352 million yen and unallocated corporate expenses totaling (2,202) million yen have been included in the segment income adjustment totaling (1,850) million yen. Corporate expenses refer to Noevir Holdings Co., Ltd.'s administration costs, which do not come under any reportable segments.

(Note 2) Segment income refers to operating income as reported in the quarterly consolidated statements of income, after adjustment.

2. Impairment loss for non-current assets and goodwill, by reportable segment

Not applicable

II Consolidated results for the first nine months of the fiscal year ending September 30, 2026
(October 1, 2025 to June 30, 2026)

1. Net sales and income (loss) data, by reportable segment

(Millions of yen)

	Cosmetics	Pharmaceuticals & Health Food	Other	Total	Adjustment (Note 1)	Amounts included in quarterly consolidated statements of income (Note 2)
Net sales						
Revenue from contracts with customers	36,422	8,002	1,579	46,004	—	46,004
Other revenue	—	—	71	71	—	71
Sales, external	36,422	8,002	1,650	46,075	—	46,075
Intersegment sales	—	—	216	216	(216)	—
Total	36,422	8,002	1,867	46,292	(216)	46,075
Segment income (loss)	8,084	562	155	8,803	(1,907)	6,895

(Note 1) Intersegment eliminations totaling 347 million yen and unallocated corporate expenses totaling (2,255) million yen have been included in the segment income adjustment totaling (1,907) million yen. Corporate expenses refer to Noevir Holdings Co., Ltd.'s administration costs, which do not come under any reportable segments.

(Note 2) Segment income refers to operating income as reported in the quarterly consolidated statements of income, after adjustment.

2. Impairment loss for non-current assets and goodwill, by reportable segment

(Significant impairment loss related to non-current assets)

The Company wrote down the carrying amount of land that it decided to sell to the recoverable amount and recognized the write-down as an impairment loss.

The impairment loss recognized for the first nine months of fiscal 2026 amounted to 120 million yen in the Pharmaceuticals & Health Food segment.